PEBP1 and lung carcinoma: These results represent a pivotal step forward in understanding the potential of blood RKIP and pRKIP as biomarkers for the early diagnosis of lung cancer, paving the way for more effective, non-invasive diagnostic tools that could transform patient outcomes and alter the course of this devastating disease.